Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus versus standard regimen in de novo senior renal transplant recipients
2008-005109-20Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus and basiliximab in kidney allograft rejection (2 arms), sponsored by Novartis. Started Mar 2009; status: completed.
02
Drugs
everolimusbasiliximab
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2008-005109-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005109-20.